Rialto Wealth Management’s United Therapeutics UTHR Stock Holding History

Rialto Wealth Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.88K	Buy	9 +2	+29%	+$1.13K	﹤0.01%	755
2026 Q1	$4.15K	Buy	7 +3	+75%	+$1.49K	﹤0.01%	630
2025 Q4	$1.95K	Hold	4	–	–	﹤0.01%	752
2025 Q3	$1.68K	Sell	4 -1	-20%	-$336	﹤0.01%	721
2025 Q2	$1.44K	Buy	5 +2	+67%	+$598	﹤0.01%	702
2025 Q1	$925	Buy	+3	New	+$1.03K	﹤0.01%	680

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Rialto Wealth Management's UTHR Position: Q2 2026 in Review

Rialto Wealth Management increased its United Therapeutics (UTHR) stake by 29% in Q2 2026, buying an estimated $1.13K and bringing the position to 9 shares worth $4.88K. The position accounts for ﹤0.01% of the portfolio, ranked #755.

Rialto Wealth Management first reported a position in UTHR in Q1 2025 and has held it in 6 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Rialto Wealth Management held 9 shares of United Therapeutics worth $4.88K as of Q2 2026.
Rialto Wealth Management bought 2 United Therapeutics shares in Q2 2026, an estimated $1.13K.
United Therapeutics made up ﹤0.01% of Rialto Wealth Management's portfolio in Q2 2026, its #755 holding.
Rialto Wealth Management first reported a position in United Therapeutics in Q1 2025 and has held it in 6 quarters since.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Rialto Wealth Management's 13F filing for Q2 2026, filed 11 Aug 2026.